vs
LCI INDUSTRIES（LCII）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
LCI INDUSTRIESの直近四半期売上が大きい（$932.7M vs $790.2M、UNITED THERAPEUTICS Corpの約1.2倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 2.0%、差は44.1%）。LCI INDUSTRIESの前年同期比売上増加率が高い（16.1% vs 7.4%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $64.3M）。過去8四半期でUNITED THERAPEUTICS Corpの売上複合成長率が高い（8.0% vs -1.8%）
ラッキーコア・インダストリーズ・リミテッドは旧ICIパキスタンとして知られるパキスタンの複合企業グループで、本社をカラチに置き、ポリエステル、医薬品、農業化学品、ソーダ灰、獣医薬品などの製造・供給を行っています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
LCII vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $932.7M | $790.2M |
| 純利益 | $18.7M | $364.3M |
| 粗利率 | 22.1% | 86.9% |
| 営業利益率 | 3.8% | 45.1% |
| 純利益率 | 2.0% | 46.1% |
| 売上前年比 | 16.1% | 7.4% |
| 純利益前年比 | 95.7% | 20.9% |
| EPS（希薄化後） | $0.79 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $932.7M | $790.2M | ||
| Q3 25 | $1.0B | $799.5M | ||
| Q2 25 | $1.1B | $798.6M | ||
| Q1 25 | $1.0B | $794.4M | ||
| Q4 24 | $803.1M | $735.9M | ||
| Q3 24 | $915.5M | $748.9M | ||
| Q2 24 | $1.1B | $714.9M | ||
| Q1 24 | $968.0M | $677.7M |
| Q4 25 | $18.7M | $364.3M | ||
| Q3 25 | $62.5M | $338.7M | ||
| Q2 25 | $57.6M | $309.5M | ||
| Q1 25 | $49.4M | $322.2M | ||
| Q4 24 | $9.5M | $301.3M | ||
| Q3 24 | $35.6M | $309.1M | ||
| Q2 24 | $61.2M | $278.1M | ||
| Q1 24 | $36.5M | $306.6M |
| Q4 25 | 22.1% | 86.9% | ||
| Q3 25 | 24.4% | 87.4% | ||
| Q2 25 | 24.4% | 89.0% | ||
| Q1 25 | 24.1% | 88.4% | ||
| Q4 24 | 21.1% | 89.7% | ||
| Q3 24 | 24.0% | 88.9% | ||
| Q2 24 | 25.3% | 89.1% | ||
| Q1 24 | 23.1% | 89.2% |
| Q4 25 | 3.8% | 45.1% | ||
| Q3 25 | 7.3% | 48.6% | ||
| Q2 25 | 7.9% | 45.6% | ||
| Q1 25 | 7.8% | 48.2% | ||
| Q4 24 | 2.0% | 48.6% | ||
| Q3 24 | 5.9% | 45.8% | ||
| Q2 24 | 8.6% | 44.7% | ||
| Q1 24 | 6.0% | 52.6% |
| Q4 25 | 2.0% | 46.1% | ||
| Q3 25 | 6.0% | 42.4% | ||
| Q2 25 | 5.2% | 38.8% | ||
| Q1 25 | 4.7% | 40.6% | ||
| Q4 24 | 1.2% | 40.9% | ||
| Q3 24 | 3.9% | 41.3% | ||
| Q2 24 | 5.8% | 38.9% | ||
| Q1 24 | 3.8% | 45.2% |
| Q4 25 | $0.79 | $7.66 | ||
| Q3 25 | $2.55 | $7.16 | ||
| Q2 25 | $2.29 | $6.41 | ||
| Q1 25 | $1.94 | $6.63 | ||
| Q4 24 | $0.37 | $6.23 | ||
| Q3 24 | $1.39 | $6.39 | ||
| Q2 24 | $2.40 | $5.85 | ||
| Q1 24 | $1.44 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $222.6M | $2.9B |
| 総負債低いほど良い | $945.2M | — |
| 株主資本純資産 | $1.4B | $7.1B |
| 総資産 | $3.2B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.69× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $222.6M | $2.9B | ||
| Q3 25 | $199.7M | $2.8B | ||
| Q2 25 | $191.9M | $3.0B | ||
| Q1 25 | $231.2M | $3.3B | ||
| Q4 24 | $165.8M | $3.3B | ||
| Q3 24 | $161.2M | $3.3B | ||
| Q2 24 | $130.4M | $3.0B | ||
| Q1 24 | $22.6M | $2.7B |
| Q4 25 | $945.2M | — | ||
| Q3 25 | $947.8M | — | ||
| Q2 25 | $948.0M | — | ||
| Q1 25 | $938.3M | — | ||
| Q4 24 | $757.3M | — | ||
| Q3 24 | $822.5M | — | ||
| Q2 24 | $829.7M | — | ||
| Q1 24 | $855.3M | — |
| Q4 25 | $1.4B | $7.1B | ||
| Q3 25 | $1.4B | $6.6B | ||
| Q2 25 | $1.4B | $7.2B | ||
| Q1 25 | $1.4B | $6.8B | ||
| Q4 24 | $1.4B | $6.4B | ||
| Q3 24 | $1.4B | $6.1B | ||
| Q2 24 | $1.4B | $5.7B | ||
| Q1 24 | $1.4B | $5.3B |
| Q4 25 | $3.2B | $7.9B | ||
| Q3 25 | $3.2B | $7.4B | ||
| Q2 25 | $3.2B | $7.9B | ||
| Q1 25 | $3.1B | $7.7B | ||
| Q4 24 | $2.9B | $7.4B | ||
| Q3 24 | $3.0B | $7.1B | ||
| Q2 24 | $3.0B | $6.7B | ||
| Q1 24 | $3.0B | $6.5B |
| Q4 25 | 0.69× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | 0.68× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.58× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.63× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.9M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $64.3M | $173.3M |
| FCFマージンFCF / 売上 | 6.9% | 21.9% |
| 設備投資強度設備投資 / 売上 | 1.6% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 4.22× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $278.3M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.9M | $346.2M | ||
| Q3 25 | $97.2M | $562.1M | ||
| Q2 25 | $112.2M | $191.7M | ||
| Q1 25 | $42.7M | $461.2M | ||
| Q4 24 | $106.6M | $341.2M | ||
| Q3 24 | $78.4M | $377.2M | ||
| Q2 24 | $192.9M | $232.2M | ||
| Q1 24 | $-7.7M | $376.5M |
| Q4 25 | $64.3M | $173.3M | ||
| Q3 25 | $80.9M | $351.6M | ||
| Q2 25 | $99.5M | $129.5M | ||
| Q1 25 | $33.7M | $386.3M | ||
| Q4 24 | $95.7M | $254.5M | ||
| Q3 24 | $68.3M | $300.7M | ||
| Q2 24 | $180.2M | $187.1M | ||
| Q1 24 | $-16.3M | $338.3M |
| Q4 25 | 6.9% | 21.9% | ||
| Q3 25 | 7.8% | 44.0% | ||
| Q2 25 | 9.0% | 16.2% | ||
| Q1 25 | 3.2% | 48.6% | ||
| Q4 24 | 11.9% | 34.6% | ||
| Q3 24 | 7.5% | 40.2% | ||
| Q2 24 | 17.1% | 26.2% | ||
| Q1 24 | -1.7% | 49.9% |
| Q4 25 | 1.6% | 21.9% | ||
| Q3 25 | 1.6% | 26.3% | ||
| Q2 25 | 1.2% | 7.8% | ||
| Q1 25 | 0.9% | 9.4% | ||
| Q4 24 | 1.4% | 11.8% | ||
| Q3 24 | 1.1% | 10.2% | ||
| Q2 24 | 1.2% | 6.3% | ||
| Q1 24 | 0.9% | 5.6% |
| Q4 25 | 4.22× | 0.95× | ||
| Q3 25 | 1.55× | 1.66× | ||
| Q2 25 | 1.95× | 0.62× | ||
| Q1 25 | 0.86× | 1.43× | ||
| Q4 24 | 11.17× | 1.13× | ||
| Q3 24 | 2.20× | 1.22× | ||
| Q2 24 | 3.15× | 0.83× | ||
| Q1 24 | -0.21× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LCII
| Travel Trailer And Fifth Wheels | $378.4M | 41% |
| Chassis Chassis Partsand Slideout Mechanisms | $206.1M | 22% |
| Furnitureand Mattresses | $120.4M | 13% |
| Appliances | $69.9M | 7% |
| Other Products | $69.1M | 7% |
| Axlesand Suspension Solutions | $62.3M | 7% |
| Motorhomes | $34.2M | 4% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
